Galderma

We’re excited to share that new interim long-term data on our treatment in atopic dermatitis have been published in the Journal of the European Academy of Dermatology and Venereology (JEADV).   This publication underscores our ongoing commitment to advancing dermatological science to help address the unmet needs of people living with chronic skin conditions.   Learn more here: https://lnkd.in/gkW-tBxm   #ForHCPs #AdvancingDermatology #SkinScienceByGalderma

At Galderma, we take pride in making a positive impact on people’s lives while building a lasting legacy in dermatology. Our continued investment in the U.S., a dynamic and strategic market, is central to this goal. Over the past two years, we have increased our U.S. headcount by 30% and opened our new U.S. and LATAM headquarters in Miami, FL. We have also expanded our research footprint with a global R&D hub in Boston, MA, and our global Skinovation LabTM in Carlsbad, CA.   In 2025 alone, we trained a record number of healthcare professionals. Our U.S.-born, industry leading Galderma Aesthetic Injector Network (GAIN)—which celebrates its 10th anniversary this year—trained more than 50,000 participants at around 2,000 training events. In parallel, our educational teams across Dermatological Skincare and Therapeutic Dermatology trained more than 1,000 physicians.   We are also investing significantly in U.S. manufacturing, expanding final assembly and packaging for our novel biologic in Florida, and manufacturing flagship Dermatological Skincare products through U.S.-based partners. In addition, we have initiated two U.S. technology transfers focused on key growth drivers, including double-sourcing U.S. capacity of our ready-to-use liquid neuromodulator powered by PEARL™ Technology.   Looking ahead, we are committed to investing more than 650 million USD in U.S. manufacturing by 2030 – advancing scientifically, commercially and operationally toward becoming a true dermatology powerhouse.   #AdvancingDermatology #USinvestments

Did you know that 25% of children worldwide are affected by atopic dermatitis? Whilst many may picture dry skin or the occasional rash, the disruption goes far beyond the skin surface, potentially leading to disturbed sleep, and hindering participation in activities and social development.     We also cannot ignore the broader impact; for parents, having a child suffering with atopic dermatitis can take an emotional toll and be disruptive for the whole family. This International Day of Care and Support, find out more about the deeper impact of atopic dermatitis on the whole family: http://bit.ly/47tiikR #AdvancingDermatology #SkinScienceByGalderma

Our inaugural GAIN Athens event was an outstanding success. Across two days, we welcomed 350+ aesthetic practitioners and hosted 8 distinguished faculty members, alongside engaging panel discussions covering topics such as skin quality, medication-driven weight loss, and GAIN business. We extend our sincere recognition to our esteemed faculty for their invaluable expertise and leadership, as well as to every attendee who shared their vision and enthusiasm for Building a Lifelong Aesthetic Journey and those behind the scenes who made this happen. #GAINAthens #GAIN10years

We’re proud to share the latest edition of our LinkedIn newsletter, Skin Deep by Galderma, in which we are highlighting the burden of atopic dermatitis. In this edition, we explore patient perspectives on the impact of atopic dermatitis, the importance of educating HCPs on itch, and Galderma’s commitment to eczema advocacy. At Galderma, we’re committed to advancing dermatology and amplifying the voices of those living with itch-related conditions. Join us in raising awareness and driving innovation in skin science. Read the newsletter below and follow us for future editions. #AdvancingDermatology #SkinScienceByGalderma

The rapid evolution of medication-driven weight loss and its implications for aesthetic medicine is increasingly prevalent worldwide and was on the agenda at #GAINAthens. Today, the audience explored new patient profiles, evidence-based approaches to restoring facial harmony, and strategies to help practitioners adapt to new clinical challenges. Hear our panel of distinguished speakers Dr. Walter Refkalefsky Loureiro, Dr. Regina Sosoaca and Dr. Maya Sinai share their perspectives on the new patient profile in their regions and how industry leaders can advance practitioner education and patient care. #GAINAthens #GAIN10years #weightloss

A heartfelt thank you to our esteemed faculty for making the first-ever GAIN Athens edition such an incredible success. Your dedication and expertise brought together Galderma’s distributors from across the region, setting a new standard for collaboration and excellence in aesthetics. Throughout these two inspiring days, the patient cases presented showcased the continuum in aesthetics and highlighted Galderma’s unwavering commitment to advancing education and empowering practitioners to deliver the best outcomes for patients. Your insights and passion are driving forces behind shaping the future of our field. Thank you for your invaluable contributions, and for leading the way in supporting the next generation of aesthetic trends and best practices. #GAIN10years #GAINATHENS

Today, Galderma announced record net sales for the first nine months of 2025, including robust growth in the in the U.S., where we achieved +17.5% year-over-year growth at constant currency. This performance was driven by the continued success of our novel biologic for prurigo nodularis and atopic dermatitis. With the recent inauguration of our new U.S. and LATAM headquarters in Miami, along with substantial ongoing investments in our operational footprint, R&D hubs, and healthcare professional educational initiatives, we are continually expanding our U.S. presence. Discover more about Galderma’s Q3 2025 performance here: https://lnkd.in/etg7c9bc #Q3results #GALD #US

We’re proud to report another quarter of record net sales at Galderma. In the first nine months of 2025, we delivered 3.737 billion USD in net sales, up 15.0% year-on-year at constant currency. Growth was widespread across all geographies and product categories, including Injectable Aesthetics (+10.5%) and Dermatological Skincare (+8.2%), supported by multiple launches in our flagship brands. Therapeutic Dermatology (+40.4%) was driven by the continued success of our novel biologic for atopic dermatitis and prurigo nodularis. In Q3, we reinforced our scientific leadership in dermatology with a strong presence at major congresses and through world-class educational programs. This included sharing the latest advances in sensitive skin and itch at EADV 2025, and delivering GAIN programs to advance best practices in aesthetics. Galderma continues to expand its U.S. operations and has committed to spend more than 650 million USD on U.S. manufacturing through 2030. Based on the strong growth trajectory across our portfolio, we have raised our 2025 full-year guidance on net sales to +17.0-17.7% year-on-year growth at constant currency. Read more about Galderma’s Q3 2025 performance here: https://lnkd.in/etg7c9bc #AdvancingDermatology #Q3results #GALD

What’s new with ALASTIN™? A refreshed brand identity and the launch of the U.S. ALASTIN Aesthetician Program mark exciting new beginnings. Over the weekend, aestheticians from across the U.S. gathered to explore ALASTIN’s breakthrough science and to be introduced to a new professional community focused on education and connection. The ALASTIN Aesthetician Program offers advanced training, scientific insights, and business resources designed to empower skincare professionals to elevate every patient experience. We’re proud to continue another chapter in advancing dermatology for every skin story. #AlastinByGalderma #AdvancingDermatology